Genetron Health
Specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
Launch date
Employees
Market cap
AUD196m
Enterprise valuation
AUD159m (Public information from Mar 2024)
Share price
$4.025 GTH
Beijing China (HQ)
Financials
Estimates*
CNY | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 109m | 248m | 323m | 424m | 532m | 651m | 765m |
% growth | - | 127 % | 31 % | 31 % | 25 % | 22 % | 18 % |
EBITDA | (431m) | (233m) | (626m) | (3.0b) | (460m) | (546m) | - |
% EBITDA margin | (395 %) | (94 %) | (193 %) | (718 %) | (87 %) | (84 %) | - |
Profit | (453m) | (512m) | (676m) | (3.1b) | (496m) | (808m) | - |
% profit margin | (416 %) | (207 %) | (209 %) | (723 %) | (93 %) | (124 %) | - |
R&D budget | 49.3m | 78.6m | 91.7m | 149m | 254m | 290m | - |
R&D % of revenue | 45 % | 32 % | 28 % | 35 % | 48 % | 45 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
* | CNY50.0m | Series A | |
N/A | Series B | ||
N/A | N/A | Series C | |
$71.0m | Series D | ||
N/A | N/A | IPO | |
Total Funding | AUD120m |
Related Content
Recent News about Genetron Health
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Genetron Health
EditACQUISITION by Genetron Health Oct 2023